In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Assessing the risk for cardiovascular diseases using PROCAM/HeartScore in obese patients. A survey with 960 employees

Session Poster Session III - Friday 08:30 - 12:30

Speaker Regine Gottfried

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Obesity
  • Session type : Poster Session

Authors : S Hossain (Bad Oeynhausen,DE), A Raethling (Bad Oeynhausen,DE), R Gottfried (Bad Oeynhausen,DE), T Bitter (Bad Oeynhausen,DE), O Oldenburg (Bad Oeynhausen,DE), G Noelker (Bad Oeynhausen,DE), K Gutleben (Bad Oeynhausen,DE), D Horstkotte (Bad Oeynhausen,DE), KP Mellwig (Bad Oeynhausen,DE)

S Hossain1 , A Raethling1 , R Gottfried1 , T Bitter1 , O Oldenburg1 , G Noelker1 , K Gutleben1 , D Horstkotte1 , KP Mellwig1 , 1Heart and Diabetes Center NRW, Ruhr-University of Bochum, Department of Cardiology - Bad Oeynhausen - Germany ,


Purpose :
Obesity has long been identified as important risk factor for a number of health problems. Body Mass Index (BMI) is the most frequently used measure to determine levels of body fat, provides a proxy measure of total adiposity (the amount of fat around the body). The aim of the present project is to apply the PROCAM and HeartScore for association of adiposity with morbidity and mortality of cardiovascular diseases in employees of different companies undergoing a cardiovascular screening program.

Method :
960 employees of different companies were investigated between May 2013 –September 2014. The cardiovascular risk was determined using the PROCAM score (allows the early detection of the risk of contracting a disease thereby providing the possibility of a timely prevention, especially in high risk groups whose disorders have not manifested clinically yet) and HeartScore (The tool for predicting and managing the risk of heart attack in Europe).

Results :
We examined 388 women and 572 men (age 43±10.77 years). 134 employees (13.96%) had BMI values above 30 kg/m2. The PROCAM-Score was = 20 in 5 employees of the adiposity group (3.73%) and in 14 of the non-adiposity group (1.90%). HeartScore was = 5 in 19 patients (14.18%) of the adiposity group and in 55 patients (6.66%) of the non-adiposity group. Increased systolic  and diastolic  blood pressure  (> 140 / > 90 mmHg) was found in 31.34 % of the obese patients and in 13.44 % of the non-obese group. However there was a slightly higher amount of smokers in the obese group (36.57%) compared to the non-obese group (34.99%).

The percentage of high LDL-Cholesterol levels was almost double in the obese group (20.9 % vs. 11.86 %). The percentage of high HbA1c values was almost five times higher in the obese group (14.93 % vs. 3.15 %).

There was an approximate 3:1 ratio of males to females in our obese collective.

Conclusion :

Although there was only a small percentage of obese employees (~15%), the significant higher risk for cardiovascular disease was apparent in both score systems (more than double). Therefore extensive diagnostic measures in prevention are required.

Total number

BMI(kg/m2) (mw/range)

HeartScore total number

PROCAM total number

HeartScore (mw/range)



Group A (BMI >30)

134/960= 13.96%


30 - 47.9






1 - 16


0 - 54

Group B (BMI<30)

826/960= 86.04%

24.03±3.05/ 16.3 - 29.9






1 - 15


0 - 45

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are